Novo, Lilly’s shares drop as Trump vows weight-loss drug price cuts
By Stine Jacobsen, Bhanvi Satija and Sriparna Roy COPENHAGEN (Reuters) -Shares of weight-loss drug makers Novo Nordisk and Eli Lilly fell on Friday after U.S. President Donald Trump said that the price of Novo’s popular Ozempic treatment would be lowered. Although Ozempic is approved to treat diabetes, it has been frequently used in the United States …
Novo, Lilly’s shares drop as Trump vows weight-loss drug price cuts Read More »









